- Home
- CLPR vs ANVS Comparison
CLPR vs ANVS Comparison
Compare CLPR & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CLPR | ANVS |
|---|---|---|
| Founded | 2015 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 59.1M | 111.3M |
| IPO Year | 2015 | 2019 |
Fundamental Metrics
Financial Performance| Metric | CLPR | ANVS |
|---|---|---|
| Price | $3.20 | $2.56 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $13.50 |
| AVG Volume (30 Days) | 57.3K | ★ 314.1K |
| Earning Date | 06-05-2026 | 01-01-0001 |
| Dividend Yield | ★ 12.18% | N/A |
| EPS Growth | N/A | ★ 62.92 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $109,997,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 5.82 | N/A |
| 52 Week Low | $3.04 | $1.11 |
| 52 Week High | $4.68 | $5.50 |
Technical Indicators
Market Signals| Indicator | CLPR | ANVS |
|---|---|---|
| Relative Strength Index (RSI) | 39.77 | 46.57 |
| Support Level | $3.04 | $2.27 |
| Resistance Level | $3.96 | $2.63 |
| Average True Range (ATR) | 0.13 | 0.19 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 34.78 | 34.62 |
Price Performance
Historical ComparisonAbout CLPR Clipper Realty Inc.
Clipper Realty Inc is a self-administered and self-managed real estate company. It acquires, owns, manages, operates, and repositions multifamily residential and commercial properties in the New York metropolitan area, with a portfolio in Manhattan and Brooklyn. It has classified its reporting segments into Residential Rental Properties and Commercial Rental Properties. The company derives its revenue mostly from the Residential segment.
About ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.